Dose escalation of RG6344 demonstrates safety and promising activity in BRAF V600E solid tumours

Treatment management of favourable risk and very favourable risk patients

Phase I/II trial shows promising activity of invikafusp alfa in PD-1–resistant GI cancers

Nivolumab plus ipilimumab improves survival results in MSI-H/dMMR metastatic colorectal cancer

Key insights from head and neck research at ASCO 2025

Future of chemotherapy and targeted therapies

Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG

Advancements in gastrointestinal cancer treatments at ASCO 2025

Updates on gastrointestinal cancer treatments ASCO 2025

Clinical advances in cancer molecular testing: the patient's perspective

Florida Atlantic University and Memorial Cancer Institute collaboration

Transforming cancer care in India: The Access Cancer Care Initiative